Andy Pasternak Buys Shares of Context Therapeutics
Andy Pasternak acquired 45,000 shares of Context Therapeutics on June 24, 2026.
Key Points
- Andy Pasternak purchased 45,000 shares of Context Therapeutics, listed on NasdaqCM as CNTX, on June 24, 2026.
- Shares of CNTX traded near $0.56 on Saturday, with a market cap of approximately $51.5 million and a 52-week range of $0.55 to $3.62.
- Several insiders, including Andy Pasternak, made similar purchases, and analysts have set a strong buy consensus with a mean target price of $5.38.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Andy Pasternak recently acquired 45,000 shares of Context Therapeutics Inc. (NasdaqCM: CNTX) on June 24, 2026. This insider buying activity comes as the stock traded near $0.56 on the same day. Context Therapeutics, a biotech firm specializing in cancer treatment, currently has a market capitalization of about $51.5 million.
Other Institutional Activity in Context Therapeutics
Several institutional investors have shown interest in Context Therapeutics. Soleus Capital Management, L.P. opened a new position with 6,963,141 shares valued at approximately $18.2 million. Similarly, Octagon Capital Advisors LP also initiated a stake with 5,250,000 shares worth about $13.8 million. Meanwhile, Blue Owl Capital Holdings LP reduced its holdings by 2,343,891 shares, leaving it with 5,089,015 shares valued at roughly $13.3 million.
Context Therapeutics Inc. Stock Up 51.2%
Shares of Context Therapeutics traded near $0.56 on Saturday. The company, which is part of the biotechnology sector, has a 52-week low of $0.55 and a high of $3.62. Its 50-day moving average is $2.01, and the 200-day moving average is $1.78. With a beta of 1.611, the stock is considered more volatile than the market. The company has a strong liquidity position with a current ratio of 8.955 and a quick ratio of 8.345.
$CNTX stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Context Therapeutics Inc.
On June 24, 2026, several insiders, including Andy Pasternak, Karen Smith, Jennifer Evans Stacey, Linda West, and Luke Nathaniel Walker, each bought 45,000 shares of Context Therapeutics. These transactions were not part of a pre-arranged trading plan. Earlier in the year, on February 19, 2026, Jennifer Lynn Minai-Azary, the Chief Financial Officer, purchased 275,000 shares.
Analysts Set New Price Targets
Analysts have maintained their bullish outlook on Context Therapeutics. On June 16, 2026, Maxim Group maintained its buy rating with a price target of $4.0. Earlier, on March 24, 2026, D. Boral Capital and Guggenheim reiterated their buy ratings with targets of $9.0 and $5.0, respectively. Overall, the consensus among analysts is a strong buy, with a mean target price of $5.38 based on eight analyst opinions.
About Context Therapeutics
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania. It focuses on developing innovative cancer treatments, particularly for solid tumors. The company is working on CTIM-76, a bispecific antibody targeting Claudin 6, in collaboration with Integral Molecular. Led by CEO Martin A. Lehr, Context Therapeutics operates with a small team of 15 employees.
Bottom Line
Andy Pasternak's purchase of Context Therapeutics shares signals insider confidence amid a volatile market. The stock's recent trading activity and strong buy ratings from analysts highlight its potential interest to investors. However, as with all 13F filings and insider transactions, these actions are historical and may not reflect current positions.
Get Context Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $CNTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.